Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$10.61 USD
+0.09 (0.86%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.67 +0.06 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDTX 10.61 +0.09(0.86%)
Will CDTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Other News for CDTX
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
Cidara Therapeutics announces new appointment to its Scientific Advisory Board